Bladder cancer is among the ten most common cancers in the United States. Although it is often diagnosed and treated early, the disease can return in certain people.
By gathering information about diet and lifestyle, researchers at Kaiser Permanente Northern California and Southern California, in collaboration with Roswell Park Comprehensive Cancer Center in Buffalo, NY, are trying to find out whether your lifestyle choices including physical activity and diet have any effect on disease recurrence and your health after bladder cancer diagnosis. Furthermore, by collecting tumor tissues and other biospecimens from you, researchers are aimed to find out whether any biomarkers or tumor features can help predict disease recurrence and offer additional insights on improving cancer care.
Eligibility
The Be-Well Study enrolled male and female patients who were diagnosed with non-muscle invasive (superficial) bladder cancer from 2015-2019. Study participants were 18 years of age or older at enrollment and members of Kaiser Permanente Northern California or Kaiser Permanente Southern California.
Participation
Participation in the study initially involved the following activities:
-
Sign an informed consent form
-
Complete an initial telephone interview
-
Give a blood sample and urine sample at time of enrollment
-
Complete follow-up telephone interviews and provide urine and saliva samples one year and two years after the first interview
-
Give permission to access your Kaiser Permanente medical record
During the follow-up period, study activities include the following:
- Sign an informed consent form or addendum
- Complete a follow-up telephone interview
- Give permission to access your Kaiser Permanente medical record
- Give permission to collect tumor tissues
Collaborating Institutions
This study is conducted by researchers at Kaiser Permanente Northern California Division of Research (Pleasanton, CA); Kaiser Permanente Southern California Department of Research and Evaluation (Pasadena, CA); Roswell Park Comprehensive Cancer Center (Buffalo, NY); University at Buffalo (Buffalo, NY); and Baylor College of Medicine (Houston, TX).
This study is made possible thanks to funding from the National Cancer Institute (R01CA172855, 3R01CA172855-04S1, R01CA257480, U01CA280991).
